Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date

NCT00691483 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00691483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00691483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2008
Completion date
December 31, 2009
Enrollment
659 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation